Percutaneous Coronary Intervention (PCI)
Use of transradial access for STEMI percutaneous coronary intervention increased from 2009 to 2015.
Percutaneous coronary intervention does not increase exercise time more than a placebo procedure in patients with angina and severe coronary stenosis.
Alternative antiplatelet therapy after percutaneous coronary intervention in patients with a CYP2C19 loss-of-function allele may have lower risk of MACE compared to clopidogrel.
A substudy analyzed whether PCI outcomes using second generation drug eluting stents were comparable to CABG in patients with low or intermediated complexity left main coronary artery disease.
Women and minorities undergoing PCI with everolimus-eluting stents have a risk of MACE similar to that of white men.
Vitamin D did not produce a substantial preventive effect on cardiac injury during percutaneous coronary intervention.
For patients with atrial fibrillation who undergo percutaneous coronary intervention, the risk of bleeding is lower with dual therapy vs triple therapy.
In patients undergoing percutaneous coronary intervention for either STEMI or NSTEMI, bivalirudin and heparin produce similar outcomes.
Coronary artery bypass grafting yielded better outcomes in patients with type 1 diabetes who had multivessel disease compared with percutaneous coronary intervention.
Coronary computed tomography angiography is an accurate method of assessing angiographic outcomes after bioresorbable vascular scaffold implantation.
Sildenafil-coated stents may help reduce clots.
Gender has no effect on the outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention receiving clopidogrel, prasugrel, or ticagrelor.
Patients with HbA1c levels had lower 7-year incidence of major adverse cardiac and cerebrovascular events compared with patients with higher HbA1c levels.
Both iFR and FFR groups experienced similar rates of composite nonfatal myocardial infarction, unplanned revascularization, or all-cause death within 1 year post-procedure.
Researchers found similar rates of target-vessel failure in both scaffold and stent percutaneous coronary intervention (PCI).
Revised coronary revascularization criteria rated whether coronary interventions are appropriate in tables organized according to practice patterns.
Researchers found that same-day discharge in PCI for non-ST-segment elevation acute coronary syndromes.
A longer wait between administration of antiplatelet therapy and primary percutaneous intervention has been linked to improved coronary reperfusion.
Under scrutiny, incidence of PCI in New York state decreased from 18.2% to 10.6% between 2010-2014.
Researchers studied the safety and efficacy of cangrelor in patients receiving unfractionated heparin for PCI.
Target lesion failure was 5.8% at 1 year after implantation with the SYNERGY stent.
Same day discharge in percutaneous coronary intervention and transradial intervention has been associated with lowered costs among Medicare beneficiaries.
RenalGuard therapy was linked to significantly reduced incidences of contrast-induced acute kidney injury.
Direct admission to a primary percutaneous coronary intervention center for ST-segment elevation myocardial infarction was associated with lower 12-month mortality.
No major differences in MACE or stent thrombosis were shown between the 2 drug-eluting stents after 10 years of follow-up.
Higher SYNTAX scores may predict major cardiovascular events in patients with coronary artery disease and diabetes.
Although current guidelines recommend delaying noncardiac surgery for 6 to 12 months after drug-eluting stent implantation, new data suggest surgery may be performed earlier.
Routine follow-up coronary angiography has no long-term clinical benefit in patients who have undergone percutaneous coronary intervention.
After multivariate adjustment, no significant in-hospital mortality difference was found between centers with and without on-site cardiac surgery.
The highest relative risk of ischemic stroke after percutaneous coronary intervention was seen during the first 2 days following the procedure.
The Cardiology Advisor Articles
- Continuous Furosemide Infusion Superior to Bolus Furosemide in Heart Failure
- ACC/AHA Release 2017 Quality Measures for STEMI/NSTEMI Management
- Role of Coffee Consumption in Heart Failure, Stroke Outcomes
- Atrial Fibrillation Survival Better With Cardiac Surgery, Cox-Maze IV
- Borderline Pulmonary Hypertension Commonly Found During Right Heart Catheterization
- Heart Failure Related to Methamphetamine Use: Possible New Epidemic?
- Cardiac Surgery: Restrictive vs Liberal Threshold for Red-Cell Transfusion
- High-Sensitivity Cardiac Troponin I Threshold Identifies Patients at Low Risk for MI, Death
- Hospital Readmissions Reduction Program Decreases Heart Failure Readmissions
- Canakinumab May Lower Lung Cancer Incidence in Patients With Atherosclerosis